Joshua J. Skydel

Mar 29, 2023 | pressofatlanticcity.com | Joshua J. Skydel

Drugmaker Eli Lilly recently said it will drop prices on some versions of insulin, and cap monthly out-of-pocket costs at $35 per product for insured individuals not covered by Medicare's prescription drug program, which also maintains a $35 cap. The welcome move comes as lawmakers in both major parties seek to control rising drug prices, but our patients and the rest of the country can't afford to rely on the good will of the pharmaceutical industry to stem the crisis. That will take legislation.

Mar 9, 2023 | koreatimes.co.kr | Joshua J. Skydel |Reshma Ramachandran

By Joshua Skydel and Reshma RamachandranDrugmaker Eli Lilly on Wednesday said it will drop prices on some versions of insulin, and cap monthly out-of-pocket costs at $35 per product for insured individuals not covered by Medicare's prescription drug program, which also maintains a $35 cap.

Mar 7, 2023 | grandhaventribune.com | Joshua J. Skydel |Reshma Ramachandran

Drugmaker Eli Lilly on Wednesday said it will drop prices on some versions of insulin, and cap monthly out-of-pocket costs at $35 per product for insured individuals not covered by Medicare’s prescription drug program, which also maintains a $35 cap. The welcome move comes as lawmakers in both major parties seek to control rising drug prices, but our patients and the rest of the country can’t afford to rely on the good will of the pharmaceutical industry to stem the crisis.

Mar 6, 2023 | twincities.com | Joshua J. Skydel |Reshma Ramachandran

BC-DRUG-COSTS-COMMENTARY:BZ     03-06Commentary: Want to make drugs, including insulin, affordable? End patent abuse(ATTENTION EDITORS: 1 photo accompanies this column.

Mar 3, 2023 | baltimoresun.com | Reshma Ramachandran |Joshua J. Skydel

Drugmaker Eli Lilly on Wednesday said it will drop prices on some versions of insulin, and cap monthly out-of-pocket costs at $35 per product for insured individuals not covered by Medicare's prescription drug program, which also maintains a $35 cap. The welcome move comes as lawmakers in both major parties seek to control rising drug prices, but our patients and the rest of the country can't afford to rely on the good will of the pharmaceutical industry to stem the crisis.